Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17057328 | 0.87 | RAB9A (0.33) | RAB9ANPC1KMT2A | |
| SCHEMBL5501263 | 0.87 | RAB9A (0.33) | RAB9ANPC1KMT2A | |
| SCHEMBL12077274 | 0.83 | MCOLN3 (0.35) | MCOLN3L3MBTL1RAB9ANPC1CHRM2 | |
| SCHEMBL18044954 | 0.81 | CHRNB2 (0.36) | — | |
| SCHEMBL29925123 | 0.80 | — | — | |
| SCHEMBL5035956 | 0.73 | SOST (0.35) | — | |
| SCHEMBL300382 | 0.71 | CHRNB2 (0.39) | MEN1KMT2A | |
| SCHEMBL3333210 | 0.71 | CHRNB2 (0.47) | — | |
| SCHEMBL3333112 | 0.71 | CHRNB2 (0.47) | — | |
| SCHEMBL3333599 | 0.71 | CHRNB2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| US-20180258085-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| US-9975890-B2 | Bicyclic AZA compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-05-22 | — | — | US | disclosed |
| US-20170247369-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9669013-B2 | Bicyclic aza compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-20160128996-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-9266857-B2 | Bicyclic AZA compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1485086-A1 | AZABICYCLIC, AZATRICYCLIC AND AZASPIROCYCLIC DERIVATIVES OF AMINOCYCLOHEXANE AS NMDA, 5HT3, AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2003080046-A1 | AZABICYCLIC, AZATRICYCLIC AND AZASPIROCYCLIC DERIVATIVES OF AMINOCYCLOHEXANE NMDA, 5HT3, AND NEURONAL NICOTINIC RECEPTOR ANTAGONI STS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | MCOLN3 1330/4885L3MBTL1 3399/4885RAB9A 1485/4885 |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM5 | MCOLN3 1311/4885L3MBTL1 3507/4885RAB9A 1355/4885 |
| US-20180258085-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | MCOLN3 1330/4885L3MBTL1 3399/4885RAB9A 1485/4885 |
| US-20170247369-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | MCOLN3 1330/4885L3MBTL1 3399/4885RAB9A 1485/4885 |
| US-20160128996-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM5 | MCOLN3 1311/4885L3MBTL1 3507/4885RAB9A 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.